Specialty chemicals company DuPont de Nemours Inc. is evaluating options for its nutrition and biosciences segment, including a sale, spinoff or tax-free merger, Bloomberg News reported, citing people familiar with the matter.

DowDuPont Inc. changed its name to DuPont de Nemours Inc. following its break-up.

The nutrition and biosciences segment could reportedly be valued at a minimum of $20 billion. Givaudan SA, Koninklijke DSM NV, Kerry Group PLC and International Flavors & Fragrances Inc. could be potential candidates for a tax-free merger, according to the report.

However, the review is in the early stages, and the company may opt not to pursue a potential sale, the people told Bloomberg News.

DuPont de Nemours booked a net loss attributable to DuPont common stockholders of $571 million in the second quarter ended June 30, with net sales falling 7% on a yearly basis.